Ann: Appendix 4C Quarterly Activity Report, page-226

I haven't followed MSB threads since the rejection of the previous FDA approval. I got out at a big loss in the 2. However, I am lucky because, after almost a year, the SP is even under 2 now. I can see further slumping of the SP shortly.

Sadly I see so many holders got stuck here. Also the illusional expectation of ARDS' EUA approval.
Look at some facts.


Roughly 34200 people die of flu in the US per annum.
covid deaths in the US is now 354 a day(from a peak of 4000), 106000 a year. Once it has reached full immunisations or herd immunity, we could even see the death rate brought down to the same level of influenza.
Sadly MSB has missed the boat when covid was at its peak. The chance of it getting used after the rapid rollout of vaccines is diminishing (regardless of FDA approval). There's never a need for expensive alternative medicine ($100k) to save someone with flu. Why do you think covid victims should be treated the same when the death rate is somehow similar to the flu?



Holders should drop the hope for it to be a covid saviour.
I am not disputing for its claimed benefits in other use. I wish it's a success so I can reinvest and make my loss back.
good luck all.